Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis

2018 ◽  
Vol 17 (7) ◽  
pp. 683-693 ◽  
Author(s):  
Lillian Barra ◽  
Grace Yang ◽  
Christian Pagnoux
2018 ◽  
Vol 55 (6) ◽  
pp. 888-899 ◽  
Author(s):  
Jae Hyun Jung ◽  
Young Ho Lee ◽  
Gwan Gyu Song ◽  
Han Saem Jeong ◽  
Jae-Hoon Kim ◽  
...  

2018 ◽  
Vol 68 (1) ◽  
pp. 313
Author(s):  
J.H. Jung ◽  
Y.H. Lee ◽  
G.G. Song ◽  
H.S. Jeong ◽  
J.-H. Kim ◽  
...  

Cureus ◽  
2021 ◽  
Author(s):  
Manusha Thapa Magar ◽  
Sunam Kafle ◽  
Arisa Poudel ◽  
Priyanka Patel ◽  
Ivan Cancarevic

2022 ◽  
Vol 12 ◽  
Author(s):  
Yue Zeng ◽  
Jianan Duan ◽  
Ge Ge ◽  
Meixia Zhang

BackgroundTakayasu’s arteritis (TA) is a rare, chronic granulomatous large-vessel vasculitis that can lead to ocular ischemia. Ocular outcomes after therapeutic management in TA remain largely unknown. We herein conduct a case-based systematic review to address the current treatment options in this particular cohort.MethodsPubMed, Medline, and EMBASE databases were searched pertaining to ocular outcomes after systemic treatment in TA. Studies reporting ocular examinations before and after treatment in TA patients with ocular ischemia were included. Clinical characteristics, therapies, ocular outcomes, and complications were recorded.ResultsA 29-year-old woman with newly diagnosed TA showed dramatic regression of Takayasu’s retinopathy (TR) following balloon angioplasty. Optical coherence tomography angiography (OCTA) was used as a novel strategy for subsequent follow-up. A total of 117 eyes of 66 patients with a median age of 27 years were included for systematic review. TR was the most common ocular manifestation. Oral steroids were prescribed in nearly all patients (n = 65), followed by the use of methotrexate and antiplatelet therapy. Of the patients, 65.8% and 34.2% underwent open surgery and endovascular procedure, respectively. The median follow-up period was 12 weeks (interquartile range 8–33.5). Surgical therapy showed better ocular improvement (including visual and imaging responses) in both acute and chronic vision loss, along with fewer complications than medical therapy alone. In the surgical group, the visual prognosis was significantly better in patients with initial visual acuity better than 20/200 (p = 0.03) and those who underwent surgery before stage III TR (p = 0.01). Ocular outcomes were equivalent in the two surgical approaches.ConclusionClinicians should be familiar with ophthalmic manifestations of this potentially treatable complication in TA. Compared with medical therapy alone, surgical intervention might be a better choice for both acute and chronic vision loss. Surgery is best recommended before the onset of irreversible ischemia to the globe. A combined regimen (oral steroids, immunosuppressants, and antiplatelet drugs) might be effective for those with surgical contradictions or reluctance to an invasive procedure. Physicians should be aware of the importance of ocular examinations, including OCTA, during the diagnosis and follow-up in TA.


2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.


Sign in / Sign up

Export Citation Format

Share Document